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We studied the presence of primary resistance to raltegravir (RAL), natural polymorphisms, and selection pressure on HIV-1
integrase. We found a high frequency of integrase polymorphisms related to the resistance to RAL and sequence stability. Fur-
ther studies are needed to determine the importance of these polymorphisms to RAL resistance.
Raltegravir (RAL) is the first integrase (IN) inhibitor to havebeen approved and is indicated for HIV-1 patients who are
resistant to multiple antiretroviral agents (4, 8, 11). Studies have
shown that three point mutations with or without secondary mu-
tations can lead to RAL resistance: N155H (L74M, E92Q, G163R),
Q148H/K/R (E138K, G140S/A), and Y143R (4). Transmission of
resistant HIV-1 viruses is a concern and can affect therapeutic
strategies. It is not clear whether genetic polymorphisms influence
the antiretroviral efficacy of RAL. In this study, we examined the
frequency of transmitted resistance mutations and naturally oc-
curring polymorphisms in HIV-1 B and non-B subtypes and the
selective pressure on IN domains. A total of 100 HIV-1-infected
patients with highly active antiretroviral therapy (HAART) failure
were included in our study (HIV RNA  5,000 copies/ml and T
CD4 cell count  350 cells/mm3). Each patient was naïve with
respect to IN inhibitors, and all patients received different
HAART schemes. A total of 34% of the patients were receiving 2
nucleoside reverse transcriptase inhibitors (NRTI) plus 1 protease
inhibitor (PI), 22% 2 NRTI plus 1 non-NRTI (NNRTI), 16% 2
NRTI plus 2 PIs, 10% 3NRTI plus 1 PI, 7% 2NRTI plus 1 NNRTI
plus 1 PI, 3% 1 NRTI plus 1 NNRTI plus 1 PI, 2% 3 NRTI plus 1
NNRTI, 2% 2 NRTI plus 3 PIs, 1% 3 NRTI, 1% 1 NRTI plus 1 PI,
1% 1 NRTI plus 1 NNRTI plus 1 PI, and 1% 2 NRTI plus sulfa-
methoxazole and trimethoprim (Bactrim). Samples were col-
lected between 2006 and 2007. The study was approved by the
Ethics Committees and the Institutional Review Board of the Fed-
eral University of Sao Paulo (no. 0595/09). We analyzed three
functional IN domains: the N-terminal domain (NTD; amino ac-
ids 1 to 50), the catalytic core domain (CCD; 51 to 212), and the
C-terminal domain (CTD; 213 to 288). HIV-1 RNAwas extracted
from plasma by the use of a QIAamp viral RNA minikit, and
reverse transcription was performed using SuperScript III reverse
transcriptase (Invitrogen, Carlsbad, CA) and nested PCR to am-
plify 1,085 bp of the IN gene. The sequencingwas performedusing
an ABI Prism 3130 Genetic Analyzer (Applied Biosystems Inc.,
Foster City, CA).
The sequences were analyzed using Sequencher version 4.2
software (Gene Code, Ann Arbor, MI). Alignments were per-
formed using Bioedit software (Carlsbad, CA). The mutations
were determined using the National Agency for Aids Research
(11). Polymorphisms were examined according to Low et al. (7).
The Nei-Gojobori method was used to calculate the ratio of non-
synonymous to synonymous evolutionary changes (dS/dN) (3).
Each subtype was mapped to a phylogenetic tree (bootstrap with
1,000 replications). The recombinant strains were analyzed using
the Rega HIV subtyping tool. Phylogenetic relationships between
the individual sequence types were determined using the neigh-
bor-joining algorithmofMEGAversion 4 software (MEGA4:Mo-
lecular Evolutionary Genetics Analysis). Frequencies of resistance
mutations were calculated using the Fisher exact test (Minitab
version 16). ThemeanCD4T-cell count andmedianHIV-1 load
were 102.65 cells/mm3 (range, 2 to 249) and 4.66 log10 copies/ml
(range, 3.70 to 5.87), respectively. Among the subjects in the
study, 43 were females and 60 were born in the city of São Paulo.
The overall analysis revealed that 85% of patients were infected
with subtype B and 6%with subsubtype F1. Phylogenetic analysis
classified 9% of the sequences as BF1 recombinants. Figure 1
shows the phylogenetic tree map of the 80 full-length sequences.
Overall data among the NTD, CCD, and CTD of the IN region
showed dS/dN values  1. As expected, the residues involved in
catalytic activity and zinc binding were fully conserved. No trans-
mission of mutations associated with resistance to RAL was ob-
served in the 100 sequences; however, we did find a secondary
mutation, G163R/E/V/Q (9%), and the following polymorphisms
related to reduced sensitivity to RAL in vitro: V72I (59%), L74I/M
(3%), T97A (1%), T125A/V/M/Q (36%), V151I (18%), M154L
(3%), M154I (1%), K156N/R (14%), E157Q (1%), V165I (10%),
V201I (54%), I203M (5%), T206S (13%), and S230N/G (8%)
(Fig. 2). The V201I and T125A polymorphisms showed in-
creased frequencies in non-B clades, which reached levels of
93% and 46% in the non-B subtypes versus 47% and 30% in the
B subtypes, respectively. The M154I was present only in the
non-B clades (6.7%), unlike S230N, which was present only in
the B subtypes at a frequency of 9.4%. The T206S and L74I
polymorphisms did not correlate with a subtype. Despite the
absence of mutations associated with transmission of resis-
tance to RAL, we found a high frequency of polymorphisms,
previously described (8), related to the reduced sensitivity to
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RAL in vitro. We also observed the G163R polymorphism,
which is capable of restoring viral fitness associated with
N155H (12). It is unknown whether G163E/V/Q has a similar
role in the IN gene. In fact, in other studies realized with Bra-
zilian samples, a high proportion of patients presenting with
accessory mutations and natural polymorphisms was revealed
(1, 9). On the other hand, in another Brazilian study, the au-
thors observed low levels of mutations associated with trans-
FIG1 Phylogenetic analysis of integrase sequences encompassing 288 amino acids. The treewas constructed using the neighbor-joining (NJ)method andMEGA
version 4 software. Bootstrap analysis was performed with 1,000 replications. Filled circles represent the subtype B sequences, and filled squares represent the F1
subtype.
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mitted resistance to RAL (6). The dS/dN values indicated an
absence of selection pressure. Because the patients in our study
were naïve with respect to IN inhibitors, it is possible that
inhibitors that target other HIV-1 enzymes indirectly applied
selection pressure on the IN gene, as observed by Ceccherini-
Silberstein et al. (3). Their study found a higher frequency of
select IN polymorphisms in AIDS-associated retrovirus
(ARV)-treated patients than in drug-naïve patients. We no-
ticed a high frequency of non-B strains, including BF recombi-
nants, which are more polymorphic than the B subtype (5).
Garrido et al. found that polymorphisms such as T206S, L74I,
T125A, and V201I were significantly more frequent in non-B
strains than in the clade B viruses, unlike M154I, E157Q, and
S230R/N, which were found more frequently in the B clade (5).
That result is in agreement with our findings, with the excep-
tions of L74I and T206S, which did not correlate with a sub-
type, and M154I, which was absent in the B clade. Despite the
associations between the genetic polymorphisms and the
HIV-1 subtypes that we observed, note that we analyzed only a
few non-B samples. We also observed that the BF recombinants
were not restricted to the city of Santos, where they were first
reported and showed an increased frequency, but were also
present in other regions of Brazil (2). According to our results,
the HIV-1 IN gene is a polymorphic gene andmay influence the
genetic barrier to RAL treatment. We did not find mutations in
residues critical for HIV-1 IN activity, and IN stabilization was
maintained. We conclude that RAL would benefit patients who
are naïve with respect to integrase inhibitors and who have
failed multiple ARV regimens. Further studies are needed to
determine the importance of these polymorphisms in reducing
FIG2 Amino acid alignment of integrase sequences showingmain secondarymutations and polymorphisms. The header shows theHXB2 amino acid consensus
obtained from the Los Alamos HIV sequence database. ●, no amino acid exchange in relation to HXB2 consensus sequence AF033819.
Mantovani et al.
2124 jcm.asm.org Journal of Clinical Microbiology
the genetic barrier to RAL resistance, especially in HIV-1
non-B subtypes.
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